OPS — Opsens Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- CA$334.82m
- CA$325.92m
- CA$48.35m
Brief: Opsens Receives Final Order For Arrangement With Haemonetics
Brief: Opsens Obtains Regulatory Clearance Of Arrangement In US And Canada
Brief: OpSens- Independent Proxy Advisory Firm ISS Recommends Shareholders Vote "For"
Brief: Opsens Announces Positive Clinical Results From Safe-Tavi Study With Savvywire In Europe
Press Digest: Canada - Oct 11
Haemonetics rises after all-cash deal to acquire OpSens
Brief: Opsens Signs Definitive Agreement For Its Acquisition By Haemonetics
Brief: Haemonetics Corporation Announces Definitive Agreement To Acquire Opsens
Brief: Opsens Says Q2 Revenue Rose 33% To C$10.8 Mln
Canada Research Roundup: Loblaw Companies, New Pacific Metals, Osisko Gold Royalties
Brief: Opsens Appoints John Hannigan As Chief Financial Officer
Brief: OpSens Awarded Interventional Specialty Diagnostics Agreement With Premier For SavvyWire
Brief: OpSens Announces First Quarter Fiscal 2023 Financial Results
Brief: Opsens Announces Filing Of Preliminary Base Shelf Prospectus
Brief: Opsens Announces Fourth Quarter And Fiscal Year 2022 Financial Results
Brief: Opsens Announces Departure Of CFO Robin Villeneuve
Brief: Opsens Announces FDA Clearance For The Savvywire™ For Use In Transcatheter Aortic Valve Replacement (TAVR) Procedures
Brief: OpSens Posts Quarterly Loss Per Share $0.03
Brief: Opsens Awarded Interventional Specialty Diagnostics Agreement With Premier For Optowire III